BR0215424A - Compostos, uso de um ou mais compostos, e, processo para fabricação de composições farmacêuticas para o tratamento de distúrbios - Google Patents
Compostos, uso de um ou mais compostos, e, processo para fabricação de composições farmacêuticas para o tratamento de distúrbiosInfo
- Publication number
- BR0215424A BR0215424A BR0215424-2A BR0215424A BR0215424A BR 0215424 A BR0215424 A BR 0215424A BR 0215424 A BR0215424 A BR 0215424A BR 0215424 A BR0215424 A BR 0215424A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- pharmaceutical compositions
- treating disorders
- manufacturing pharmaceutical
- preparation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000002045 Endothelin Human genes 0.000 abstract 1
- 108050009340 Endothelin Proteins 0.000 abstract 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0200002 | 2002-01-02 | ||
| PCT/EP2002/013970 WO2003055863A1 (en) | 2002-01-02 | 2002-12-10 | Novel alkansulfonamides as endothelin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0215424A true BR0215424A (pt) | 2004-12-14 |
Family
ID=8164767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0215424-2A BR0215424A (pt) | 2002-01-02 | 2002-12-10 | Compostos, uso de um ou mais compostos, e, processo para fabricação de composições farmacêuticas para o tratamento de distúrbios |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7323465B2 (enExample) |
| JP (1) | JP4769418B2 (enExample) |
| KR (1) | KR100940432B1 (enExample) |
| CN (1) | CN100537546C (enExample) |
| AR (1) | AR037943A1 (enExample) |
| AT (1) | ATE381545T1 (enExample) |
| AU (1) | AU2002361033B8 (enExample) |
| BR (1) | BR0215424A (enExample) |
| CA (1) | CA2471220C (enExample) |
| DE (1) | DE60224223T2 (enExample) |
| ES (1) | ES2297040T3 (enExample) |
| HU (1) | HUP0500082A2 (enExample) |
| IL (2) | IL162534A0 (enExample) |
| MX (1) | MXPA04006457A (enExample) |
| MY (1) | MY138502A (enExample) |
| NO (1) | NO327220B1 (enExample) |
| NZ (1) | NZ533693A (enExample) |
| TW (1) | TWI248436B (enExample) |
| WO (1) | WO2003055863A1 (enExample) |
| ZA (1) | ZA200404927B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2682849C (en) * | 2007-04-03 | 2012-05-29 | Pfizer Inc. | Sulfonamides and pharmaceutical compositions thereof |
| IT1393136B1 (it) * | 2009-03-11 | 2012-04-11 | Sifa Vitor S R L | Procedimento per la preparazione del bosentan |
| US20100256371A1 (en) * | 2009-04-02 | 2010-10-07 | Glenmark | Processes for the preparation of bosentan and its intermediates thereof |
| AR077999A1 (es) * | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| EP2907811A1 (en) * | 2014-02-14 | 2015-08-19 | Actelion Pharmaceuticals Ltd. | Process for manufacturing pyrimidine sulfamide derivatives |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739333A (en) * | 1995-05-16 | 1998-04-14 | Tanabe Seiyaku Co., Ltd. | Sulfonamide derivative and process for preparing the same |
| JP3013752B2 (ja) * | 1995-05-16 | 2000-02-28 | 田辺製薬株式会社 | スルホンアミド誘導体 |
| ATE201202T1 (de) * | 1995-12-20 | 2001-06-15 | Yamanouchi Pharma Co Ltd | Arylethensulfonamid-derivate und diese enthaltende medikamente |
| AU3459697A (en) * | 1996-07-23 | 1998-02-10 | Shionogi & Co., Ltd. | Novel pyrimidine compounds and drug compositions |
| JP3116347B2 (ja) * | 1996-11-13 | 2000-12-11 | 田辺製薬株式会社 | 医薬組成物 |
| WO1998057938A1 (en) * | 1997-06-19 | 1998-12-23 | Yamanouchi Pharmaceutical Co., Ltd. | Substituted lower alkanesulfonamide derivatives and pharmaceutical composition containing the same |
| NZ512526A (en) * | 1999-09-03 | 2004-01-30 | Actelion Pharmaceuticals Ltd | 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin. |
| GB0023074D0 (en) * | 2000-09-20 | 2000-11-01 | Pfizer Ltd | Pyridazines |
-
2002
- 2002-12-10 MX MXPA04006457A patent/MXPA04006457A/es active IP Right Grant
- 2002-12-10 CA CA2471220A patent/CA2471220C/en not_active Expired - Fee Related
- 2002-12-10 HU HU0500082A patent/HUP0500082A2/hu unknown
- 2002-12-10 IL IL16253402A patent/IL162534A0/xx unknown
- 2002-12-10 ES ES02795133T patent/ES2297040T3/es not_active Expired - Lifetime
- 2002-12-10 CN CNB028266447A patent/CN100537546C/zh not_active Expired - Fee Related
- 2002-12-10 DE DE60224223T patent/DE60224223T2/de not_active Expired - Lifetime
- 2002-12-10 AU AU2002361033A patent/AU2002361033B8/en not_active Ceased
- 2002-12-10 NZ NZ533693A patent/NZ533693A/en not_active IP Right Cessation
- 2002-12-10 US US10/500,485 patent/US7323465B2/en not_active Expired - Fee Related
- 2002-12-10 JP JP2003556394A patent/JP4769418B2/ja not_active Expired - Fee Related
- 2002-12-10 BR BR0215424-2A patent/BR0215424A/pt not_active IP Right Cessation
- 2002-12-10 KR KR1020047010218A patent/KR100940432B1/ko not_active Expired - Fee Related
- 2002-12-10 WO PCT/EP2002/013970 patent/WO2003055863A1/en not_active Ceased
- 2002-12-10 AT AT02795133T patent/ATE381545T1/de active
- 2002-12-19 AR ARP020105030A patent/AR037943A1/es active IP Right Grant
- 2002-12-26 TW TW091137487A patent/TWI248436B/zh not_active IP Right Cessation
- 2002-12-30 MY MYPI20024923A patent/MY138502A/en unknown
-
2004
- 2004-06-15 IL IL162534A patent/IL162534A/en not_active IP Right Cessation
- 2004-06-22 ZA ZA2004/04927A patent/ZA200404927B/en unknown
- 2004-07-29 NO NO20043215A patent/NO327220B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2471220C (en) | 2010-11-16 |
| WO2003055863A1 (en) | 2003-07-10 |
| CA2471220A1 (en) | 2003-07-10 |
| KR20040073525A (ko) | 2004-08-19 |
| AR037943A1 (es) | 2004-12-22 |
| DE60224223D1 (de) | 2008-01-31 |
| TWI248436B (en) | 2006-02-01 |
| HUP0500082A2 (hu) | 2005-04-28 |
| TW200404063A (en) | 2004-03-16 |
| AU2002361033A1 (en) | 2003-07-15 |
| IL162534A (en) | 2011-07-31 |
| US7323465B2 (en) | 2008-01-29 |
| NZ533693A (en) | 2007-02-23 |
| ZA200404927B (en) | 2005-11-30 |
| DE60224223T2 (de) | 2008-12-04 |
| JP4769418B2 (ja) | 2011-09-07 |
| IL162534A0 (en) | 2005-11-20 |
| JP2005513155A (ja) | 2005-05-12 |
| US20050085639A1 (en) | 2005-04-21 |
| MXPA04006457A (es) | 2004-10-04 |
| AU2002361033B8 (en) | 2009-01-29 |
| MY138502A (en) | 2009-06-30 |
| KR100940432B1 (ko) | 2010-02-10 |
| AU2002361033B2 (en) | 2008-11-20 |
| NO20043215L (no) | 2004-07-29 |
| ATE381545T1 (de) | 2008-01-15 |
| CN1612864A (zh) | 2005-05-04 |
| NO327220B1 (no) | 2009-05-18 |
| ES2297040T3 (es) | 2008-05-01 |
| CN100537546C (zh) | 2009-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0408681A (pt) | compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos | |
| BR0116505A (pt) | Compostos ou um sal deste farmaceuticamente aceitável, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios onde um antagonista de um receptor de orexina humano é requerido, e, processo para a fabricação de composições farmacêuticas para o tratamento de distúrbios associados com o papel da orexina, especialmente da obesidade e distúrbios do sono | |
| BR0314353A (pt) | Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio | |
| BR0312000A (pt) | Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, uso dos compostos | |
| BRPI0109200B8 (pt) | compostos e composições farmacêuticas | |
| BR0315115A (pt) | Compostos, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios em que se requer um antagonista de receptores de orexina humana, processo para a fabricação de composições farmacêuticas, e, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BR0113358A (pt) | Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável | |
| BR0113755A (pt) | Composto multimérico, processo para a preparação de composto, composição farmacêutica que compreende o composto, processo para o tratamento e/ou profilaxia e detecção de uma infecção por virus, utilização do composto, e inalador que contém a composição | |
| BR0111335A (pt) | Derivado de quinazolina, processo para a preparação de um derivado de, quinazolina, composição farmacêutica, e, uso de um derivado de quinazolina | |
| BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| BRPI0116237B8 (pt) | "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina". | |
| BR9810592A (pt) | Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto | |
| BR0211284A (pt) | Derivados de 1-fenilsulfonil-1,3-dihidro-2h-indol-2-ona, a respectiva preparação e a respectiva aplicação em terapêutica | |
| BR0208489A (pt) | Derivados de n-(arilsulfonil) beta-aminoácidos, comportando um grupo aminoetilado substituìdo, o respectivo processo de preparação e as composições farmacêuticas que os contêm | |
| BR9907270A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto | |
| BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
| BRPI0507604A (pt) | medicamentos com atividade de receptor hm74a | |
| BRPI0414772A (pt) | derivado de quinazolina, composto, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, método para produzir um efeito anti-proliferativo em um animal de sangue quente | |
| BRPI0407253A (pt) | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos | |
| BRPI0206636B8 (pt) | composição e atividade antiviral de derivados de piperazina azaindoloxoacéticos substituídos, composições farmacêuticas que os contêm e usos | |
| BRPI0512796A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf, e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença | |
| BR0208887A (pt) | Derivados de dihidro-benzo[b][1,4]diazepin-2-ona como antagonistas i de mglur2 | |
| BRPI0409498A (pt) | uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto | |
| BR0112337A (pt) | Derivados de fosfolipìdeos de ácido valpróico e suas misturas | |
| BRPI0409884A (pt) | compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2284 DE 14/10/2014. |